Fondaparinux (Arixtra)
Indications
| Indication | Approved Population | Therapy Type | Status |
|---|---|---|---|
| DVT prophylaxis — hip fracture surgery (incl. extended prophylaxis) | Adults | Monotherapy | FDA Approved |
| DVT prophylaxis — hip replacement surgery | Adults | Monotherapy | FDA Approved |
| DVT prophylaxis — knee replacement surgery | Adults | Monotherapy | FDA Approved |
| DVT prophylaxis — abdominal surgery | Adults at risk of thromboembolic complications | Monotherapy | FDA Approved |
| Treatment of acute DVT (with warfarin) | Adults | Bridge to warfarin | FDA Approved |
| Treatment of acute PE (with warfarin, inpatient) | Adults | Bridge to warfarin | FDA Approved |
| Treatment of VTE in paediatric patients (≥10 kg) | Paediatric (≥10 kg) | Weight-based | FDA Approved |
Fondaparinux is the first synthetic anticoagulant: a chemically defined pentasaccharide modelled on the antithrombin-binding sequence found in heparin chains. Its completely selective mechanism (Factor Xa inhibition only, no anti-IIa activity) gives it a highly predictable pharmacokinetic profile with 100% bioavailability, no CYP metabolism, and once-daily dosing. Phase II (PENTATHLON) and phase III trials (EPHESUS, PENTHIFRA, PENTAMAKS) demonstrated superior VTE prevention compared with enoxaparin in orthopaedic surgery. A key advantage is its very low risk of heparin-induced thrombocytopenia (HIT) because it does not bind platelet factor 4 (PF4).
Acute coronary syndromes (UA/NSTEMI): The OASIS-5 trial (n=20,078) showed fondaparinux 2.5 mg daily was noninferior to enoxaparin for ischaemic events and reduced major bleeding by 50% (2.1% vs 4.1%) with 17% lower 30-day mortality. ESC guidelines recommend fondaparinux as the preferred anticoagulant in NSTE-ACS when PCI is not planned within 24 hours. Evidence: High
Heparin-induced thrombocytopenia (HIT): Fondaparinux does not cross-react with HIT antibodies in most patients and is used as an alternative anticoagulant. ACCP assigns a low evidence rating; further studies are needed. Not FDA-approved for this indication. Evidence: Low
Superficial venous thrombosis (SVT): CHEST 2021 guidelines recommend fondaparinux as the preferred anticoagulant for SVT of the lower limb at risk of progression, over prophylactic or therapeutic LMWH. Evidence: Moderate
Dosing
VTE Prophylaxis by Clinical Scenario
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| Hip fracture surgery | 2.5 mg SC once daily | 2.5 mg SC once daily | 2.5 mg/day | Start 6–8 h post-op; continue up to 32 days total (peri-operative + extended prophylaxis) PENTHIFRA-Plus: extended prophylaxis reduced VTE from 35% to 1.4% |
| Hip replacement surgery | 2.5 mg SC once daily | 2.5 mg SC once daily | 2.5 mg/day | Start 6–8 h post-op; usual duration 5–9 days (up to 11 days studied) EPHESUS/PENTATHLON: fondaparinux superior to enoxaparin for VTE prevention in hip replacement |
| Knee replacement surgery | 2.5 mg SC once daily | 2.5 mg SC once daily | 2.5 mg/day | Start 6–8 h post-op; usual duration 5–9 days (up to 11 days studied) PENTAMAKS: 55% RRR in VTE vs enoxaparin; starting <6 h post-op increases bleeding risk |
| Abdominal surgery (VTE risk patients) | 2.5 mg SC once daily | 2.5 mg SC once daily | 2.5 mg/day | Start 6–8 h post-op; usual duration 5–9 days (up to 10 days studied) Contraindicated if body weight <50 kg (prophylaxis only) |
VTE Treatment (Adult, Weight-Based)
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| Acute DVT/PE — body weight <50 kg | 5 mg SC once daily | 5 mg SC once daily | 5 mg/day | Bridge to warfarin; continue ≥5 days AND until INR 2–3 for ≥24 h Usual duration 5–9 days; up to 26 days studied in clinical trials |
| Acute DVT/PE — body weight 50–100 kg | 7.5 mg SC once daily | 7.5 mg SC once daily | 7.5 mg/day | Bridge to warfarin; continue ≥5 days AND until INR 2–3 for ≥24 h MATISSE-DVT: noninferior to enoxaparin for recurrent VTE at 97 days |
| Acute DVT/PE — body weight >100 kg | 10 mg SC once daily | 10 mg SC once daily | 10 mg/day | Bridge to warfarin; continue ≥5 days AND until INR 2–3 for ≥24 h MATISSE-PE: noninferior to UFH for recurrent VTE in PE treatment |
Paediatric VTE Treatment (≥10 kg)
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| VTE treatment — paediatric (≥10 kg) | 0.1 mg/kg SC once daily | 0.1 mg/kg SC once daily (adjust by anti-Xa levels) | 7.5 mg/day | Monitor fondaparinux-based anti-Xa 2–4 h after 2nd or 3rd dose; target 0.5–1.0 mg/L Patients >20 kg: round to nearest prefilled syringe per PI table; no data for <1 year |
The first dose of fondaparinux must be given no earlier than 6 hours after surgical closure, and only once haemostasis has been established. In clinical trials, administering fondaparinux earlier than 6 hours post-operatively significantly increased the incidence of major bleeding. If surgical haemostasis is not achieved, fondaparinux initiation should be delayed until 6–8 hours after haemostasis is confirmed. For hip fracture surgery, if surgery is delayed, fondaparinux may be started pre-operatively with the last dose at least 24 hours before surgery.
There is no specific antidote for fondaparinux. Protamine sulfate does not neutralise its anti-Xa activity. In life-threatening bleeding, recombinant activated factor VII (rFVIIa, NovoSeven) has been used based on limited evidence, but its efficacy is not established. The long half-life (17–21 h) means anticoagulant effects persist for 2–4 days after the last dose in patients with normal renal function, and even longer in renal impairment. This should be considered when weighing fondaparinux against alternatives in patients at high bleeding risk.
Pharmacology
Mechanism of Action
Fondaparinux is a fully synthetic pentasaccharide that replicates the exact five-sugar sequence within heparin chains responsible for binding antithrombin III (AT-III). This binding induces a conformational change in AT-III that enhances its inhibition of Factor Xa by approximately 300-fold. Critically, because fondaparinux is only five saccharide units long (far shorter than the 18 units needed to bridge AT-III to thrombin), it selectively inhibits Factor Xa without any direct anti-thrombin (anti-IIa) activity. Once the fondaparinux–AT-III complex inactivates Factor Xa, fondaparinux dissociates and can be recycled to bind another AT-III molecule, functioning catalytically. This selective mechanism produces a predictable, dose-linear anticoagulant effect with minimal protein binding beyond AT-III, virtually eliminating the unpredictable dose-response that characterises unfractionated heparin.
ADME Profile
| Parameter | Value | Clinical Implication |
|---|---|---|
| Absorption | 100% bioavailability SC; Tmax ~2 h; rapid and complete absorption with low inter-subject variability (Cmax variability ~11.6%) | Complete and predictable absorption enables fixed-dose prophylaxis (2.5 mg) without laboratory monitoring in most patients; once-daily dosing is sufficient due to the long half-life |
| Distribution | Vd 7–11 L (limited to blood volume); >97% bound to plasma proteins, with >94% specifically to AT-III; no binding to albumin or alpha-1-acid glycoprotein | Highly specific AT-III binding means protein-binding displacement interactions with other drugs are not expected; small Vd confirms drug remains in the intravascular compartment |
| Metabolism | No metabolism — fondaparinux is not metabolised in vivo; does not inhibit CYP1A2, 2A6, 2C9, 2C19, 2D6, 2E1, or 3A4 in vitro | No hepatic metabolism eliminates CYP-mediated drug interactions; dose adjustment for hepatic impairment is not required (moderate); severe hepatic impairment has not been studied |
| Elimination | Excreted unchanged in urine (64–77% recovered at 72 h); plasma clearance 5.1–7.9 mL/min; renal clearance 4.0–7.9 mL/min; t½ 17 h (young), 21 h (elderly) | Entirely renal elimination makes fondaparinux contraindicated at CrCl <30 mL/min; in elderly patients, longer half-life may prolong anticoagulant effect — contributes to increased bleeding risk in this population; steady state reached after 3rd–4th daily dose |
Side Effects
| Adverse Effect | Incidence | Clinical Note |
|---|---|---|
| Anaemia / post-procedural haemorrhage | ~11% | Most common in surgical prophylaxis setting; includes wound drainage and post-operative bleeding at surgical site; partly attributable to the surgical procedure |
| Adverse Effect | Incidence | Clinical Note |
|---|---|---|
| Minor bleeding (haematuria, injection site bleeding, ecchymosis) | 1–4% | Dose-dependent; higher in treatment dosing than prophylaxis; typically self-limiting |
| Moderate thrombocytopenia (50,000–100,000/mm³) | 3.0% (prophylaxis); 0.5% (treatment) | Not immune-mediated; fondaparinux does not bind PF4, so HIT risk is negligible; discontinue if platelets fall below 100,000 |
| Nausea | 3% | Usually mild and transient; no dose adjustment needed |
| Elevated hepatic transaminases | 1–3% | Transient elevations in AST/ALT; generally asymptomatic and resolve spontaneously |
| Oedema | ~3% | Peripheral oedema in surgical prophylaxis patients; assess for other causes including DVT |
| Injection site reaction (rash, pruritus) | ~1% | Mild local reactions; rotate injection sites; syringe needle guard contains dry natural latex rubber — caution in latex-allergic patients |
| Adverse Effect | Estimated Frequency | Typical Onset | Required Action |
|---|---|---|---|
| Major haemorrhage | 1.6–3.0% (prophylaxis); 1.1–1.2% (VTE treatment) | Any time during therapy | Discontinue fondaparinux; supportive measures (transfusion, surgical haemostasis); no specific antidote — consider rFVIIa in life-threatening haemorrhage; effects persist 2–4 days after last dose |
| Spinal / epidural haematoma | Rare (case reports) | Hours to days after neuraxial procedure | FDA Boxed Warning; emergent spinal decompression; delay fondaparinux until ≥2 h after catheter removal; monitor for neurological impairment |
| Severe thrombocytopenia (<50,000/mm³) | 0.2% | Days to weeks | Discontinue fondaparinux; investigate for other causes; may require platelet transfusion if actively bleeding |
| Anaphylactoid / anaphylactic reactions | Rare (post-marketing) | Minutes to hours after injection | Discontinue permanently; manage with standard anaphylaxis protocol; note latex in syringe needle guard may contribute in latex-sensitive patients |
| Major bleeding with renal impairment (CrCl 30–50 mL/min) | 3.8% (prophylaxis in moderate RI) | Accumulation over days | Use with extreme caution; closely monitor renal function and signs of bleeding; bleeding risk rises steeply with declining CrCl |
Major bleeding during fondaparinux prophylaxis in orthopaedic surgery increases sharply with declining renal function: 1.6% (normal), 2.4% (mild RI), 3.8% (moderate RI), and 4.8% (severe RI) per the FDA PI. Because fondaparinux is eliminated entirely by the kidneys, drug accumulation occurs rapidly in renal impairment. Fondaparinux is contraindicated at CrCl <30 mL/min and should be used with caution at CrCl 30–50 mL/min, with close monitoring of renal function and signs of bleeding.
Drug Interactions
Fondaparinux has an exceptionally clean interaction profile. It is not metabolised by CYP enzymes and binds specifically to AT-III without significant binding to albumin or other plasma proteins, so pharmacokinetic interactions via protein-binding displacement or hepatic metabolism are not expected. Clinical studies confirmed no pharmacokinetic interactions with warfarin, aspirin, piroxicam, or digoxin. The primary interaction concern is pharmacodynamic: co-administration with other agents that impair haemostasis increases bleeding risk.
Monitoring
- Renal Function (CrCl)Baseline; periodic during therapy
RoutineCritical parameter — fondaparinux is contraindicated at CrCl <30 mL/min and requires caution at CrCl 30–50 mL/min; reassess if renal function declines during therapy; discontinue immediately if CrCl drops below 30 - Platelet CountBaseline; periodic
RoutineDiscontinue if platelets fall below 100,000/mm³; moderate thrombocytopenia occurred in 3% of prophylaxis patients and 0.5% of treatment patients; severe thrombocytopenia (<50,000) in 0.2% - CBC / HaemoglobinBaseline; periodic
RoutineUnexplained drop in haemoglobin or haematocrit should prompt evaluation for occult bleeding; stool occult blood testing recommended during therapy - Anti-Xa Level (fondaparinux-based)Paediatric: 2–4 h after 2nd–3rd dose, then periodically
Trigger-basedRequired for paediatric dosing (target 0.5–1.0 mg/L); must use fondaparinux-specific calibrator — heparin or LMWH calibrators are NOT appropriate; routine anti-Xa monitoring not required in adult prophylaxis or treatment - Signs of BleedingEvery clinical assessment
RoutineAssess surgical wound drainage, injection sites, urine, and stool; back pain or neurological symptoms after neuraxial procedure require urgent evaluation for epidural haematoma - Neurological StatusFrequently after neuraxial anaesthesia
Trigger-basedPer FDA Boxed Warning: monitor for signs of spinal cord compression (back pain, leg weakness, numbness, bowel/bladder dysfunction); urgent MRI and neurosurgical consultation if suspected
Contraindications & Cautions
Absolute Contraindications
- Severe renal impairment (CrCl <30 mL/min): Fondaparinux is eliminated entirely by the kidneys; drug accumulation and life-threatening bleeding occur with severe renal dysfunction
- Active major bleeding: Any uncontrolled haemorrhage
- Bacterial endocarditis: Risk of mycotic aneurysm rupture
- Body weight <50 kg (prophylaxis only): Increased bleeding risk at prophylactic dose; not a contraindication for weight-based VTE treatment doses
- Thrombocytopenia with positive anti-platelet antibody test in the presence of fondaparinux: Rare immune-mediated reaction
- History of serious hypersensitivity (angioedema, anaphylaxis) to fondaparinux
Relative Contraindications (Specialist Input Recommended)
- Moderate renal impairment (CrCl 30–50 mL/min): Increased drug exposure and bleeding risk; may still be used with close monitoring and clinical judgement
- Concurrent neuraxial anaesthesia or spinal puncture: Risk of spinal/epidural haematoma (FDA Boxed Warning); delay fondaparinux ≥2 hours after catheter removal
- Planned PCI within 24 hours (ACS setting): Catheter thrombus risk (0.9% in OASIS-5); requires supplemental UFH bolus at time of PCI
Use with Caution
- Elderly (≥75 years): Prolonged half-life (21 h); increased bleeding risk; lower body weight common
- Moderate hepatic impairment (Child-Pugh B): Decreased Cmax by 22% and AUC by 39% in single-dose study; higher haemorrhage incidence observed compared with normal hepatic function
- Patients undergoing PCI (ACS): Use UFH bolus at time of PCI to prevent catheter thrombus; FUTURA/OASIS-8 data support low-dose UFH (50 U/kg) as adjunct
- Latex allergy: Syringe needle guard contains dry natural latex rubber
Epidural or spinal haematomas may occur in patients anticoagulated with fondaparinux who are receiving neuraxial anaesthesia or undergoing spinal puncture. These haematomas can result in long-term or permanent paralysis. Risk is increased by indwelling epidural catheters, concomitant use of other haemostasis-impairing drugs (NSAIDs, antiplatelets, other anticoagulants), history of spinal deformity or difficult spinal puncture, and repeated puncture. Patients must be monitored frequently for signs of neurological impairment and treated urgently if spinal cord compression is suspected.
Patient Counselling
Purpose of Therapy
Explain that fondaparinux is a blood-thinning injection given once daily under the skin to prevent blood clots after surgery or to treat existing blood clots in the legs or lungs. It works by blocking a specific clotting factor (Factor Xa) and is given as a fixed dose that does not require routine blood test monitoring in most adults.
How to Take
Fondaparinux is injected once daily into the skin fold of the lower abdomen, alternating between the left and right sides. The prefilled syringe comes with an automatic needle protection system. If you are self-injecting at home, you will receive training on proper injection technique. Store syringes at room temperature (15–30°C). Each syringe is for single use only — do not reuse or share.
Sources
- ARIXTRA (fondaparinux sodium) Prescribing Information. Mylan Institutional LLC; revised December 2024. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/021345s052lbl.pdfMost current FDA label with adult and paediatric dosing, contraindications, adverse reactions, and pharmacokinetic data for fondaparinux.
- Yusuf S, Mehta SR, Chrolavicius S, et al. Comparison of fondaparinux and enoxaparin in acute coronary syndromes (OASIS-5). N Engl J Med. 2006;354(14):1464–1476. doi:10.1056/NEJMoa055443Landmark RCT (n=20,078) demonstrating fondaparinux 2.5 mg daily is noninferior to enoxaparin for ischaemic events in NSTE-ACS while halving major bleeding and reducing 30-day mortality by 17%.
- Mehta SR, Granger CB, Eikelboom JW, et al. Efficacy and safety of fondaparinux versus enoxaparin in patients with ACS undergoing PCI: results from OASIS-5. J Am Coll Cardiol. 2007;50(18):1742–1751. doi:10.1016/j.jacc.2007.07.042PCI subgroup analysis of OASIS-5 confirming bleeding reduction with fondaparinux and demonstrating that UFH co-administration at PCI prevents catheter thrombus.
- Buller HR, Davidson BL, Decousus H, et al. Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism (MATISSE-PE). N Engl J Med. 2003;349(18):1695–1702. doi:10.1056/NEJMoa035451Open-label RCT showing fondaparinux noninferior to UFH for PE treatment with similar rates of recurrent VTE and major bleeding.
- Buller HR, Davidson BL, Decousus H, et al. Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis (MATISSE-DVT). Ann Intern Med. 2004;140(11):867–873. doi:10.7326/0003-4819-140-11-200406010-00007Randomised trial demonstrating fondaparinux noninferior to enoxaparin for DVT treatment with comparable efficacy and safety at 97 days.
- Eriksson BI, Bauer KA, Lassen MR, Turpie AGG, for the Steering Committee of the Pentasaccharide in Hip-Fracture Surgery Study. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery (PENTHIFRA). N Engl J Med. 2001;345(18):1298–1304. doi:10.1056/NEJMoa011100Phase III trial showing fondaparinux reduced VTE by 56% compared with enoxaparin in hip fracture surgery prophylaxis.
- Bauer KA, Eriksson BI, Lassen MR, Turpie AGG, for the PENTAMAKS Steering Committee. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery. N Engl J Med. 2001;345(18):1305–1310. doi:10.1056/NEJMoa011099PENTAMAKS trial demonstrating 55% VTE risk reduction with fondaparinux vs enoxaparin in elective knee replacement.
- Stevens SM, Woller SC, Kreuziger LB, et al. Antithrombotic Therapy for VTE Disease: Second Update of the CHEST Guideline and Expert Panel Report. Chest. 2021;160(6):e545–e608. doi:10.1016/j.chest.2021.07.055CHEST 2021 guideline recommending fondaparinux as preferred anticoagulant for superficial venous thrombosis and covering VTE treatment and prophylaxis options.
- Paolucci F, Clavies MC, Donat F, et al. Fondaparinux sodium mechanism of action: identification of specific binding to purified and human plasma-derived proteins. Clin Pharmacokinet. 2002;41(Suppl 2):11–18. doi:10.2165/00003088-200241002-00002Key study demonstrating >94% specific binding of fondaparinux to AT-III with no binding to albumin or alpha-1-acid glycoprotein, explaining its clean drug interaction profile.
- Donat F, Duret JP, Santoni A, et al. The pharmacokinetics of fondaparinux sodium in healthy volunteers. Clin Pharmacokinet. 2002;41(Suppl 2):1–9. doi:10.2165/00003088-200241002-00001Definitive PK study establishing 100% bioavailability, 17 h half-life (21 h elderly), Vd 7–11 L, and linear pharmacokinetics across the therapeutic dose range.
- Schiele F. Fondaparinux and acute coronary syndromes: update on the OASIS 5–6 studies. Vasc Health Risk Manag. 2010;6:179–187. doi:10.2147/vhrm.s5950Comprehensive review of OASIS-5 and OASIS-6 results discussing fondaparinux’s position in ACS management, catheter thrombus risk, and PCI co-administration strategies.
- Lieu C, Shi J, Donat F, et al. Fondaparinux sodium is not metabolised in mammalian liver fractions and does not inhibit cytochrome P450-mediated metabolism of concomitant drugs. Clin Pharmacokinet. 2002;41(Suppl 2):19–26. doi:10.2165/00003088-200241002-00003In vitro study confirming fondaparinux does not undergo hepatic metabolism and does not inhibit major CYP isoenzymes, supporting its lack of pharmacokinetic drug interactions.